Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc is positioned for sustained double-digit growth, driven by increased utilization of its Light Adjustable Lens (LAL) technology and a growing installed base of LDD systems. The company anticipates potential upside from factors such as faster growth in LDD installations, enhanced utilization rates, and improved margins as LALs represent a larger share of total revenue. Furthermore, RxSight expects improvements in cash burn, indicating operational efficiencies as the company's revenue mix evolves favorably.

Bears say

RxSight Inc. faces significant challenges that contribute to a negative financial outlook, primarily due to limited product adoption attributable to the necessity for additional capital equipment. The company has experienced disappointing commercial execution, compounded by increasing competition in the intraocular lens (IOL) market, which may hinder growth prospects. Furthermore, revised revenue projections indicate declines for both 2025 and 2026, with anticipated revenues adjusted down to $164 million and $205 million, respectively, suggesting more cautious market expectations.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.